Phar­varis lands an­oth­er $80M as it looks to tack­le Take­da and CSL with an oral ap­proach for HAE

A year af­ter their $66 mil­lion launch, the Swiss up­start Phar­varis has man­aged to con­vince an­oth­er fleet of new and re­turn­ing in­vestors to back their up­start ap­proach for a rare ge­net­ic con­di­tion called hered­i­tary an­gioede­ma, or HAE.

The com­pa­ny said Wednes­day that they’ve raised an $80 mil­lion Se­ries C led by Viking Glob­al In­vestors and Gen­er­al At­lantic. They’ll plow that cash di­rect­ly in­to a pair of Phase II tri­als to test whether their lead mol­e­cule can be­come the first oral drug to suc­cess­ful­ly treat and pre­vent the painful episodes HAE trig­gers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA